Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02749331 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy

Study acronym: RADNET
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 3, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Aug 2023 to Aug 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Sep 2024 to Dec 2025
    • Site details revised
    v6
  2. Primary completion date: Aug 2022 to Aug 2023
    • Study completion date: Sep 2022 to Sep 2024
    • Site contact updated
    v5
  3. Primary completion date: Aug 2020 to Aug 2022
    • Study completion date: Dec 2020 to Sep 2022
    v4
  4. Primary completion date: Aug 2019 to Aug 2020
    • Study completion date: Dec 2019 to Dec 2020
    v3
  5. Primary completion date: Aug 2018 to Aug 2019
    • Study completion date: Dec 2018 to Dec 2019
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.
Trial Details
NCT Number NCT02749331
Lead Sponsor Uppsala University
Conditions
(from sponsor)		 Neuroendocrine Tumors
Related terms Neuroendocrine Tumors
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov